JP5851493B2 - 原発性高アルドステロン症の両側性状態と片側性状態との鑑別診断のためのｐｅｔ放射性医薬 - Google Patents

原発性高アルドステロン症の両側性状態と片側性状態との鑑別診断のためのｐｅｔ放射性医薬 Download PDF

Info

Publication number
JP5851493B2
JP5851493B2 JP2013512927A JP2013512927A JP5851493B2 JP 5851493 B2 JP5851493 B2 JP 5851493B2 JP 2013512927 A JP2013512927 A JP 2013512927A JP 2013512927 A JP2013512927 A JP 2013512927A JP 5851493 B2 JP5851493 B2 JP 5851493B2
Authority
JP
Japan
Prior art keywords
compound
pyrrolidine
mmol
formula
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013512927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013534911A (ja
JP2013534911A5 (https=
Inventor
ブルーノ アローリオ
ブルーノ アローリオ
ステファニー ホーナー
ステファニー ホーナー
アンドレアス シルベル
アンドレアス シルベル
ロルフ ハルトマン
ロルフ ハルトマン
クリスティーナ ジマー
クリスティーナ ジマー
Original Assignee
ユリウス−マクシミリアンズ−ユニバーシタット
ユニバーシタット デ ザールラント
ユニバーシタット デ ザールラント
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユリウス−マクシミリアンズ−ユニバーシタット, ユニバーシタット デ ザールラント, ユニバーシタット デ ザールラント filed Critical ユリウス−マクシミリアンズ−ユニバーシタット
Publication of JP2013534911A publication Critical patent/JP2013534911A/ja
Publication of JP2013534911A5 publication Critical patent/JP2013534911A5/ja
Application granted granted Critical
Publication of JP5851493B2 publication Critical patent/JP5851493B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nuclear Medicine (AREA)
JP2013512927A 2010-06-01 2011-06-01 原発性高アルドステロン症の両側性状態と片側性状態との鑑別診断のためのｐｅｔ放射性医薬 Expired - Fee Related JP5851493B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10164663.6 2010-06-01
EP10164663A EP2394668A1 (en) 2010-06-01 2010-06-01 PET radiopharmaceuticals for differential diagnosis between bilateral and unilateral conditions of primary hyperaldosteronism
PCT/EP2011/059135 WO2011151411A1 (en) 2010-06-01 2011-06-01 Pet radiopharmaceuticals for differential diagnosis between bilateral and unilateral conditions of primary hyperaldosteronism

Publications (3)

Publication Number Publication Date
JP2013534911A JP2013534911A (ja) 2013-09-09
JP2013534911A5 JP2013534911A5 (https=) 2014-09-04
JP5851493B2 true JP5851493B2 (ja) 2016-02-03

Family

ID=42668720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013512927A Expired - Fee Related JP5851493B2 (ja) 2010-06-01 2011-06-01 原発性高アルドステロン症の両側性状態と片側性状態との鑑別診断のためのｐｅｔ放射性医薬

Country Status (4)

Country Link
US (1) US20130089502A1 (https=)
EP (2) EP2394668A1 (https=)
JP (1) JP5851493B2 (https=)
WO (1) WO2011151411A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151876A1 (en) * 2012-04-04 2013-10-10 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
JP6048958B2 (ja) 2012-12-27 2016-12-21 日本メジフィジックス株式会社 副腎疾患の画像診断剤
JP2015193545A (ja) * 2014-03-31 2015-11-05 国立大学法人京都大学 ２−（３−ピリジニル）−１ｈ−ベンズイミダゾール誘導体化合物、これを含む放射性医薬
AU2015281060B2 (en) * 2014-06-26 2019-03-14 Kyoto University 2-(3-pyridinyl)-1H-benzimidazole derivative compound and medicine containing same
EP3470091A4 (en) 2016-06-10 2019-06-19 Nihon Medi-Physics Co., Ltd. NONINVASIVE DIAGNOSTIC CONTRASTANT FOR HEART DISEASES
EP3357910A1 (en) 2017-02-02 2018-08-08 Julius-Maximilians-Universität Würzburg Compound for in vivo diagnosis of a dysfunction of adrenal glands
US11266753B2 (en) 2017-12-28 2022-03-08 Nihon Medi-Physics Co., Ltd. 2-[5-(imidazol-1-ylmethyl)pyridin-3-yl]benzimtdazole derivative compound, and medicament including same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092430A1 (de) * 2005-03-03 2006-09-08 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
DK2012833T3 (en) * 2006-05-02 2015-01-19 Univ Pennsylvania RADIOACTIVALLY LABELED DIHYDROTETRABENAZINE DERIVATIVES AND USE THEREOF AS IMAGING AGENTS
US8519134B2 (en) * 2009-11-17 2013-08-27 Novartis Ag Aryl-pyridine derivatives as aldosterone synthase inhibitors

Also Published As

Publication number Publication date
EP2394668A1 (en) 2011-12-14
JP2013534911A (ja) 2013-09-09
US20130089502A1 (en) 2013-04-11
WO2011151411A1 (en) 2011-12-08
EP2575899A1 (en) 2013-04-10

Similar Documents

Publication Publication Date Title
JP5851493B2 (ja) 原発性高アルドステロン症の両側性状態と片側性状態との鑑別診断のためのｐｅｔ放射性医薬
NO20170638A1 (no) Kontrastmidler for myokardial perfusjonsbilleddannelse
EA018655B1 (ru) Ингибиторы репликации вируса иммунодефицита человека
CN112175025B (zh) 一种含苯环的葡萄糖衍生物及其应用
JP7036802B2 (ja) Ｐｅｔ放射性トレーサとしての［１８ｆ］で標識された乳酸誘導体
Garg et al. 4-11C-methoxy N-(2-diethylaminoethyl) benzamide: a novel probe to selectively target melanoma
JP2023184564A (ja) 新規化合物
WO2020103392A1 (zh) 一种以7-脱氮腺嘌呤碱基为母核的18f-pet/ct示踪剂及其制备方法
CA2384879C (en) Nitroimidazole derivative and diagnostic imaging agent containing the same
JP6048958B2 (ja) 副腎疾患の画像診断剤
EP2900278B1 (en) Radiopharmaceutical products for diagnosis and therapy of adrenal carcinoma
JP7375755B2 (ja) 陽電子放出核種で標識された脂肪酸誘導体
CN102603647B (zh) 18/19f-酯类硝基咪唑化合物及其制备方法和作为乏氧组织显像剂的用途
CN106084004B (zh) 18f点击标记转铁蛋白受体靶向多肽t7及其制备方法和应用
WO2016097339A1 (en) Labelled coumarin derivatives
KR20220128998A (ko) 양전자 방출 핵종으로 표지된 지방산 유도체
JP7664650B2 (ja) グアノシン誘導体及びその製造法
JP6218366B2 (ja) Ｈ３受容体の放射性標識リガンド
Park et al. Synthesis and Evaluation of F‐18 Labeled Pyrido [3, 2‐B] pyrazine Derivative as a Potential Imaging Agent for Non‐Small‐Cell Lung Cancer
CN109438265B (zh) 一种与棕色脂肪组织具有亲和力的化合物及其制备方法和应用
JP2015193545A (ja) ２−（３−ピリジニル）−１ｈ−ベンズイミダゾール誘導体化合物、これを含む放射性医薬
CN118324760A (zh) 一种雌激素受体α靶向PET分子探针及其应用
CN119080714A (zh) 一种偶氮苯磺酸酯化合物及其制备方法和应用、放射性探针的制备方法
WO2014126071A1 (ja) 芳香族アミノ酸誘導体およびそれを用いるｐｅｔプローブ
WO2016097355A1 (en) Labelled oxazolidinone derivatives

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140716

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150724

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151202

R150 Certificate of patent or registration of utility model

Ref document number: 5851493

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees